Mark R. Denison MD
Professor of Pathology, Microbiology & Immunology/ Director, Division of Pediatric Infectious Diseases
Mark R. Denison, MD, is the Edward Claiborne Stahlman Professor of Pediatrics, Professor of Pathology, Microbiology & Immunology, and Director of the Division of Pediatric Infectious
Diseases at Vanderbilt University Medical Center. The Denison Lab has been NIH funded for investigation of coronavirus replication, pathogenesis, evolution, and countermeasures for over
30 years. Coronaviruses (CoVs) are a family of RNA viruses causing respiratory infections and also zoonotic infections of global importance as potential pandemic pathogens and agents of
bioterrorism, including SARS-CoV, MERS-CoV, and the current SARS-CoV-2 (COVID-19) pandemic. The Denison lab has focused on antiviral development since 2013 and initiated and led all preclinical testing for the highly active and broad spectrum anti-CoV antivirals remdesivir and EIDD-2801. The lab also has identified multiple novel targets for antivirals and virus
attenuation including the polymerase and novel proofreading exonuclease. Dr. Denison is a Fellow of SPR, APS, AAAS, the American Academy of Microbiology, and the Association of American Physicians. He has served on national and international forums and panels regarding development of policies for biosecurity and biosafety, including current membership on the
National Science Advisory Board for Biosecurity (NSABB).